New Approaches to Genetic Counseling and Testing for Alzheimer’s Disease and Frontotemporal Degeneration

[1]  B. Wilfond,et al.  Ethical issues with genetic testing in pediatrics. , 2013, Pediatrics.

[2]  O L Lopez,et al.  Genome-wide association analysis of age-at-onset in Alzheimer's disease , 2012, Molecular Psychiatry.

[3]  J. Grafman,et al.  FUS and TDP43 genetic variability in FTD and CBS , 2012, Neurobiology of Aging.

[4]  D. Neary,et al.  Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.

[5]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[6]  A. Singleton,et al.  Repeat expansion in C9ORF72 in Alzheimer's disease. , 2012, The New England journal of medicine.

[7]  Robert C Green,et al.  A comprehensive genetic association study of Alzheimer disease in African Americans. , 2011, Archives of neurology.

[8]  J. Rohrer,et al.  Phenotypic signatures of genetic frontotemporal dementia. , 2011, Current opinion in neurology.

[9]  R. Green,et al.  Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics , 2011, Clinical genetics.

[10]  D. Geschwind,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[11]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[12]  Michelle K. Lupton,et al.  Genome-wide Association Study of Alzheimer’s disease with Psychotic Symptoms , 2011, Molecular Psychiatry.

[13]  I. Litvan,et al.  Parkinsonism and Frontotemporal Dementia: The Clinical Overlap , 2011, Journal of Molecular Neuroscience.

[14]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[15]  C. Jack,et al.  Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene. , 2011, Archives of neurology.

[16]  Susan E. Hahn,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors: Erratum , 2011, Genetics in Medicine.

[17]  H. Schipper.  Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention , 2011, Alzheimer's & Dementia.

[18]  Richard Mayeux,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors , 2011, Genetics in Medicine.

[19]  J. Hodges,et al.  Neuropathological background of phenotypical variability in frontotemporal dementia , 2011, Acta Neuropathologica.

[20]  A. Kertesz.  The overlapping syndromes of the pick complex. , 2011, Current Alzheimer research.

[21]  G. Schellenberg,et al.  Familial prion disease with alzheimer disease‐like tau pathology and clinical phenotype , 2011, Annals of neurology.

[22]  P. Deyn,et al.  No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration , 2011, Neurobiology of Aging.

[23]  D. Neary,et al.  The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene , 2011, Acta Neuropathologica.

[24]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[25]  William T. Hu,et al.  Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis , 2011, Acta Neuropathologica.

[26]  S. Rapcsak,et al.  Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes , 2011, Neurology.

[27]  B. Miller,et al.  An algorithm for genetic testing of frontotemporal lobar degeneration , 2011, Neurology.

[28]  Sandro Sorbi,et al.  Meta-analysis of the association between variants in SORL1 and Alzheimer disease. , 2011, Archives of neurology.

[29]  K. Lunetta,et al.  Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.

[30]  R. Petersen,et al.  Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease , 2010, Human Genetics.

[31]  S. Faraone,et al.  Review Article: Genetics of Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.

[32]  Nick C Fox,et al.  Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[34]  James B Leverenz,et al.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.

[35]  M. Grossman,et al.  Primary progressive aphasia: clinicopathological correlations , 2010, Nature Reviews Neurology.

[36]  Nick C Fox,et al.  The heritability and genetics of frontotemporal lobar degeneration , 2009, Neurology.

[37]  J. Hardy,et al.  Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation , 2009, Neurobiology of Aging.

[38]  R. Green,et al.  Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease , 2008, Alzheimer's & Dementia.

[39]  W. Kamphorst,et al.  Distinct genetic forms of frontotemporal dementia , 2008, Neurology.

[40]  F. Collins,et al.  Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008. , 2008, The New England journal of medicine.

[41]  G. Schellenberg,et al.  Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease. , 2008, Archives of neurology.

[42]  Christine Van Broeckhoven,et al.  Molecular genetics of Alzheimer's disease: An update , 2008, Annals of medicine.

[43]  K. Sleegers,et al.  Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. , 2007, Archives of neurology.

[44]  I. Mackenzie,et al.  Progranulin: normal function and role in neurodegeneration , 2007, Journal of neurochemistry.

[45]  B. Dubois,et al.  Progranulin null mutations in both sporadic and familial frontotemporal dementia , 2007, Human mutation.

[46]  J. Schneider,et al.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.

[47]  R. Green,et al.  Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. , 2006, Patient education and counseling.

[48]  G. Schellenberg,et al.  Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. , 2006, Archives of neurology.

[49]  S. Melquist,et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.

[50]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[51]  C. D. de Jager,et al.  APOE alleles predict the rate of cognitive decline in Alzheimer disease , 2005, Neurology.

[52]  J. Neuhaus,et al.  Comparison of family histories in FTLD subtypes and related tauopathies , 2005, Neurology.

[53]  D. Campion,et al.  Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an update , 2005, Journal of Medical Genetics.

[54]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[55]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[56]  A. Goate,et al.  Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe , 2003, Human mutation.

[57]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[58]  D. Towner,et al.  Ethics of preimplantation diagnosis for a woman destined to develop early-onset Alzheimer disease. , 2002, JAMA.

[59]  S. Rechitsky,et al.  Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation. , 2002, JAMA.

[60]  T. Bird,et al.  Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. , 2001, Archives of neurology.

[61]  W. Kamphorst,et al.  Phenotypic variation in hereditary frontotemporal dementia with tau mutations , 1999, Annals of neurology.

[62]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[63]  T. Bird,et al.  Recent Advances in the Genetics of Alzheimer's Disease , 1998, Journal of geriatric psychiatry and neurology.

[64]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[65]  M. L. Schmidt,et al.  Autosomal dominant dementia with widespread neurofibrillary tangles , 1997, Annals of neurology.

[66]  A. Roses,et al.  The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.

[67]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[68]  N. Relkin,et al.  The National Institute on Aging/Alzheimer's Association Recommendations on the Application of Apolipoprotein E Genotyping to Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[69]  J. Rommens,et al.  Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. , 1996, Human molecular genetics.

[70]  J. Kaye,et al.  Increased risk of familial late-onset Alzheimer's disease in women , 1996, Neurology.

[71]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.

[72]  D. Drachman,et al.  Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease : what physicians know, and what they should know , 1995 .

[73]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[74]  E M Wijsman,et al.  A familial Alzheimer's disease locus on chromosome 1 , 1995, Science.

[75]  A. Roses.  On the metabolism of apolipoprotein E and the Alzheimer diseases , 1995, Experimental Neurology.

[76]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[77]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[78]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[79]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[80]  Ags Ethics Comittee.  Genetic testing for late-onset Alzheimer's disease. AGS Ethics Committee. , 2001, Journal of the American Geriatrics Society.

[81]  E M Wijsman,et al.  Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. , 1996, American journal of human genetics.